1. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125–8. [PubMed] [Google Scholar]
2. Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs. 2000;9(7):1651–63. [PubMed] [Google Scholar]
3. MacLean LD, Meakins JL, Taguchi K, et al. Host resistance in sepsis and trauma. Ann Surg. 1975;182(3):207–17. [PMC free article] [PubMed] [Google Scholar]
4. Munster AM. Post-traumatic immunosuppression is due to activation of suppressor T cells. Lancet. 1976;1(7973):1329–30. [PubMed] [Google Scholar]
5. Meakins JL, Pietsch JB, Bubenick O, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg. 1977;186(3):241–50. [PMC free article] [PubMed] [Google Scholar]
6. Miller CL, Baker CC. Changes in lymphocyte activity after thermal injury. The role of suppressor cells. J Clin Invest. 1979;63(2):202–10. [PMC free article] [PubMed] [Google Scholar]
7. Wolfe JH, Wu AV, O'Connor NE, et al. Anergy, immunosuppressive serum, and impaired lymphocyte blastogenesis in burn patients. Arch Surg. 1982;117(10):1266–71. [PubMed] [Google Scholar]
8. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 2001;16(2):83–96. [PubMed] [Google Scholar]
9. Shelley O, Murphy T, Paterson H, et al. Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock. 2003;20(2):123–9. [PubMed] [Google Scholar]
10. Daniels JC, Sakai H, Cobb EK, et al. Evaluation of lymphocyte reactivity studies in patients with thermal burns. J Trauma. 1971;11(7):595–601. [PubMed] [Google Scholar]
11. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun. 1997;65(6):2283–91. [PMC free article] [PubMed] [Google Scholar]
12. O'Mahony JB, Wood JJ, Rodrick ML, et al. Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to sepsis. Ann Surg. 1985;202(5):580–6. [PMC free article] [PubMed] [Google Scholar]
13. Abraham E, Chang YH. The effects of hemorrhage on mitogen-induced lymphocyte proliferation. Circ Shock. 1985;15(2):141–9. [PubMed] [Google Scholar]
14. Bandyopadhyay G, De A, Laudanski K, et al. Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med. 2007;35(3):794–801. [PubMed] [Google Scholar]
15. Stephan RN, Kupper TS, Geha AS, et al. Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg. 1987;122(1):62–8. [PubMed] [Google Scholar]
16. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg. 1999;178(4):288–92. [PubMed] [Google Scholar]
17. O'Sullivan ST, Lederer JA, Horgan AF, et al. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995;222(4):482–90. discussion 490–482. [PMC free article] [PubMed] [Google Scholar]
18. Rodrick ML, Wood JJ, Grbic JT, et al. Defective IL-2 production in patients with severe burns and sepsis. Lymphokine Res. 1986;5(Suppl 1):S75–80. [PubMed] [Google Scholar]
19. Puyana JC, Pellegrini JD, De AK, et al. Both T-helper-1- and T-helper-2-type lymphokines are depressed in posttrauma anergy. J Trauma. 1998;44(6):1037–45. discussion 1045–1036. [PubMed] [Google Scholar]
20. Wick M, Kollig E, Muhr G, et al. The potential pattern of circulating lymphocytes TH1/TH2 is not altered after multiple injuries. Arch Surg. 2000;135(11):1309–14. [PubMed] [Google Scholar]
21. Palmer JL, Tulley JM, Kovacs EJ, et al. Injury-induced suppression of effector T cell immunity requires CD1d-positive APCs and CD1d-restricted NKT cells. J Immunol. 2006;177(1):92–9. [PubMed] [Google Scholar]
22. Schwacha MG, Ayala A, Chaudry IH. Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury. J Leukoc Biol. 2000;67(5):644–50. [PubMed] [Google Scholar]
23. Krakauer T, Oppenheim JJ. IL-1 and tumor necrosis factor-alpha each up-regulate both the expression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1) J Immunol. 1993;150(4):1205–11. [PubMed] [Google Scholar]
24. Fumeaux T, Pugin J. Is the measurement of monocytes HLA-DR expression useful in patients with sepsis? Intensive Care Med. 2006;32(8):1106–8. [PubMed] [Google Scholar]
25. Volk HD, Reinke P, Docke WD. Immunological monitoring of the inflammatory process: Which variables? When to assess? Eur J Surg Suppl. 1999;(584):70–2. [PubMed] [Google Scholar]
26. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 1996;22(Suppl 4):S474–81. [PubMed] [Google Scholar]
27. Asadullah K, Woiciechowsky C, Docke WD, et al. Very low monocytic HLA-DR expression indicates high risk of infection–immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med. 1995;2(4):184–90. [PubMed] [Google Scholar]
28. van den Berk JM, Oldenburger RH, van den Berg AP, et al. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation. 1997;63(12):1846–8. [PubMed] [Google Scholar]
29. Denzel C, Riese J, Hohenberger W, et al. Monitoring of immunotherapy by measuring monocyte HLA-DR expression and stimulated TNFalpha production during sepsis after liver transplantation. Intensive Care Med. 1998;24(12):1343–4. [PubMed] [Google Scholar]
30. Haveman JW, van den Berg AP, van den Berk JM, et al. Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake. Transpl Infect Dis. 1999;1(3):146–52. [PubMed] [Google Scholar]
31. Astiz M, Saha D, Lustbader D, et al. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med. 1996;128(6):594–600. [PubMed] [Google Scholar]
32. Ding Y, Chung CS, Newton S, et al. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock. 2004;22(2):137–44. [PMC free article] [PubMed] [Google Scholar]
33. Flohe SB, Agrawal H, Schmitz D, et al. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol. 2006;79(3):473–81. [PubMed] [Google Scholar]
34. Guisset O, Dilhuydy MS, Thiebaut R, et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 2007;33(1):148–52. [PubMed] [Google Scholar]
35. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol. 2002;168(5):2493–500. [PubMed] [Google Scholar]
36. Toliver-Kinsky TE, Cui W, Murphey ED, et al. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J Immunol. 2005;174(1):404–10. [PubMed] [Google Scholar]
37. Fujita S, Seino K, Sato K, et al. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood. 2006;107(9):3656–64. [PubMed] [Google Scholar]
38. MacNeil IA, Suda T, Moore KW, et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol. 1990;145(12):4167–73. [PubMed] [Google Scholar]
39. O'Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol. 1990;2(9):821–32. [PubMed] [Google Scholar]
40. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med. 2002;30(1 Supp):S58–63. [PubMed] [Google Scholar]
41. Berg DJ, Kuhn R, Rajewsky K, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995;96(5):2339–47. [PMC free article] [PubMed] [Google Scholar]
42. Howard M, Muchamuel T, Andrade S, et al. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993;177(4):1205–8. [PMC free article] [PubMed] [Google Scholar]
43. van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. 1997;158(4):1971–5. [PubMed] [Google Scholar]
44. Remick DG, Garg SJ, Newcomb DE, et al. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med. 1998;26(5):895–904. [PubMed] [Google Scholar]
45. Steinhauser ML, Hogaboam CM, Kunkel SL, et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol. 1999;162(1):392–9. [PubMed] [Google Scholar]
46. Ashare A, Powers LS, Butler NS, et al. Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol. 2005;288(4):L633–40. [PubMed] [Google Scholar]
47. Song GY, Chung CS, Chaudry IH, et al. What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery. 1999;126(2):378–83. [PubMed] [Google Scholar]
48. Ayala A, Xin Xu Y, Ayala CA, et al. Increased mucosal B-lymphocyte apoptosis during polymicrobial sepsis is a Fas ligand but not an endotoxin-mediated process. Blood. 1998;91(4):1362–72. [PubMed] [Google Scholar]
49. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27(7):1230–51. [PubMed] [Google Scholar]
50. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101(4):890–8. [PMC free article] [PubMed] [Google Scholar]
51. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–1. [PubMed] [Google Scholar]
52. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952–63. [PubMed] [Google Scholar]
53. Hiramatsu M, Hotchkiss RS, Karl IE, Buchman TG. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. Shock. 1997;7(4):247–53. [PubMed] [Google Scholar]
54. Hotchkiss RS, Swanson PE, Cobb JP, et al. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med. 1997;25(8):1298–307. [PubMed] [Google Scholar]
55. Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock. 2002;18(6):487–94. [PubMed] [Google Scholar]
56. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol. 1999;162(7):4148–56. [PubMed] [Google Scholar]
57. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A. 1999;96(25):14541–6. [PMC free article] [PubMed] [Google Scholar]
58. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181(1):176–80. [PubMed] [Google Scholar]
59. Keane RM, Birmingham W, Shatney CM, et al. Prediction of sepsis in the multitraumatic patient by assays of lymphocyte responsiveness. Surg Gynecol Obstet. 1983;156(2):163–7. [PubMed] [Google Scholar]
60. Hynninen M, Pettila V, Takkunen O, et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock. 2003;20(1):1–4. [PubMed] [Google Scholar]
61. Oczenski W, Krenn H, Jilch R, et al. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med. 2003;29(8):1253–7. [PubMed] [Google Scholar]
62. Perry SE, Mostafa SM, Wenstone R, et al. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med. 2003;29(8):1245–52. [PubMed] [Google Scholar]
63. Ahlstrom A, Hynninen M, Tallgren M, et al. Predictive value of interleukins 6, 8 and 10, and low HLA-DR expression in acute renal failure. Clin Nephrol. 2004;61(2):103–10. [PubMed] [Google Scholar]
64. Su L, Zhou DY, Tang YQ, et al. [Clinical value of monitoring CD14+ monocyte human leukocyte antigen (locus) DR levels in the early stage of sepsis] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006;18(11):677–9. [PubMed] [Google Scholar]
65. Zhang YT, Fang Q. [Study on monocyte HLA-DR expression in critically ill patients after surgery] Zhonghua Wai Ke Za Zhi. 2006;44(21):1480–2. [PubMed] [Google Scholar]
66. Allen ML, Peters MJ, Goldman A, et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med. 2002;30(5):1140–5. [PubMed] [Google Scholar]
67. Doughty L, Carcillo JA, Kaplan S, et al. The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest. 1998;113(6):1625–31. [PubMed] [Google Scholar]
68. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65(4):1357–65. [PubMed] [Google Scholar]
69. van Dissel JT, van Langevelde P, Westendorp RG, et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet. 1998;351(9107):950–3. [PubMed] [Google Scholar]
70. Angele MK, Wichmann MW, Ayala A, et al. Testosterone receptor blockade after hemorrhage in males. Restoration of the depressed immune functions and improved survival following subsequent sepsis. Arch Surg. 1997;132(11):1207–14. [PubMed] [Google Scholar]
71. Angele MK, Catania RA, Ayala A, et al. Dehydroepiandrosterone: an inexpensive steroid hormone that decreases the mortality due to sepsis following trauma-induced hemorrhage. Arch Surg. 1998;133(12):1281–8. [PubMed] [Google Scholar]
72. Catania RA, Angele MK, Ayala A, et al. Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine. 1999;11(6):443–50. [PubMed] [Google Scholar]
73. Hershman MJ, Appel SH, Wellhausen SR. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol. 1989;77(1):67–70. [PMC free article] [PubMed] [Google Scholar]
74. Bundschuh DS, Barsig J, Hartung T, et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol. 1997;158(6):2862–71. [PubMed] [Google Scholar]
75. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678–81. [PubMed] [Google Scholar]
76. Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med. 1997;157(4):389–93. [PubMed] [Google Scholar]
77. Nakos G, Malamou-Mitsi VD, Lachana A, et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med. 2002;30(7):1488–94. [PubMed] [Google Scholar]
